[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100635853":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":28,"locations":38,"responsibleParty":128,"collaborators":130,"id":133,"slug":12,"hasResults":134,"nctId":135,"briefTitle":136,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":134,"sex":139,"minAge":140,"maxAge":12,"enrollmentInfo":141,"targetDuration":12,"studyType":144,"phases":145,"briefSummary":147,"conditions":148,"keywords":150,"overallStatus":41,"whyStopped":12,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":163},{"fullName":5,"class":6},"University Hospital, Antwerp","OTHER",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"CT arm","NO_INTERVENTION","Treatment decision guided by radiographic evaluation following the standard of care of the treating hospital. (Control arm)",null,{"label":14,"type":15,"description":16,"interventionNames":17},"Liquid Biopsy arm","EXPERIMENTAL","Treatment decision guided by liquid biopsies. (intervention arm)",[18],"Other: Evaluation therapy through Liquid Biopsy",[20],{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":12},"Evaluation therapy through Liquid Biopsy","The LB arm is the intervention group where the evaluation of therapy is guided by Liquid Biopsy results",[14],[25],{"name":26,"affiliation":5,"role":27},"Timon Vandamme","PRINCIPAL_INVESTIGATOR",[29,34],{"name":30,"role":31,"phone":32,"phoneExt":12,"email":33},"Sanne Wouters","CONTACT","003238212441","sanne.wouters@uza.be",{"name":35,"role":31,"phone":36,"phoneExt":12,"email":37},"Ayla Wyninckx","003232759745","ayla.wyninckx@uza.be",[39,52,62,71,80,90,100,109,119],{"facility":40,"status":41,"city":42,"state":43,"zip":44,"country":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":12},"AZ Sint Maarten","RECRUITING","Mechelen","Antwerpen","2800","Belgium",{"type":47,"coordinates":48},"Point",[49,50],4.47762,51.02574,{"lat":50,"lon":49},{"facility":53,"status":41,"city":54,"state":55,"zip":56,"country":45,"cosmosGeoPoint":57,"geoPoint":61,"contacts":12},"AZ Klina","Brasschaat","Antwerp","2930",{"type":47,"coordinates":58},[59,60],4.49182,51.2912,{"lat":60,"lon":59},{"facility":63,"status":41,"city":64,"state":55,"zip":65,"country":45,"cosmosGeoPoint":66,"geoPoint":70,"contacts":12},"University Hospital Antwerp","Edegem","2650",{"type":47,"coordinates":67},[68,69],4.44504,51.15662,{"lat":69,"lon":68},{"facility":72,"status":41,"city":73,"state":55,"zip":74,"country":45,"cosmosGeoPoint":75,"geoPoint":79,"contacts":12},"Sint-Augustinus (ZAS)","Wilrijk","2610",{"type":47,"coordinates":76},[77,78],4.39513,51.16734,{"lat":78,"lon":77},{"facility":81,"status":41,"city":82,"state":83,"zip":84,"country":45,"cosmosGeoPoint":85,"geoPoint":89,"contacts":12},"Grand Hopital de Charleroi","Charleroi","Henegouwen","6020",{"type":47,"coordinates":86},[87,88],4.44448,50.41136,{"lat":88,"lon":87},{"facility":91,"status":41,"city":92,"state":93,"zip":94,"country":45,"cosmosGeoPoint":95,"geoPoint":99,"contacts":12},"AZ Maria Middelares, Ghent","Ghent","Oost-Vlaanderen","9000",{"type":47,"coordinates":96},[97,98],3.71667,51.05,{"lat":98,"lon":97},{"facility":101,"status":41,"city":102,"state":93,"zip":103,"country":45,"cosmosGeoPoint":104,"geoPoint":108,"contacts":12},"Vitaz","Sint-Niklaas","9100",{"type":47,"coordinates":105},[106,107],4.1437,51.16509,{"lat":107,"lon":106},{"facility":110,"status":41,"city":111,"state":112,"zip":113,"country":45,"cosmosGeoPoint":114,"geoPoint":118,"contacts":12},"AZ Sint Lucas, Brugge","Bruges","West-Vlaanderen","8000",{"type":47,"coordinates":115},[116,117],3.22424,51.20892,{"lat":117,"lon":116},{"facility":120,"status":41,"city":121,"state":112,"zip":122,"country":45,"cosmosGeoPoint":123,"geoPoint":127,"contacts":12},"AZ Groeninge, Kortrijk","Kortrijk","8500",{"type":47,"coordinates":124},[125,126],3.26487,50.82803,{"lat":126,"lon":125},{"type":129,"investigatorFullName":12,"investigatorTitle":12,"investigatorAffiliation":12,"oldNameTitle":12,"oldOrganization":12},"SPONSOR",[131],{"name":132,"class":6},"Kom Op Tegen Kanker","100635853",false,"NCT07558083","FOLICOLOR TRIAL: Following Therapy Response Through Liquid Biopsy in Metatstatic Colorectal Cancer Patients","FOLICOLOR","Inclusion Criteria:\n\n* Man or woman ≥ 18 years of age at the time the informed consent is obtained\n* ECOG performance status of 0-2\n* Histologically or cytologically confirmed adenocarcinoma of the colon or rectum in subjects with unresectable metastatic (M1) disease\n* There should be at least 1 uni-dimensionally measurable (min. 10mm) using conventional crosssectional imaging techniques (CT or MRI scan). Lesion must not be chosen from a previously irradiated field, unlessnthere has been documented disease progression in that field after irradiation and prior to randomization. All sites of disease must be evaluated ≤ 28 days prior to randomization\n* Adequate hematology, renal, hepatic and coagulation function (at treating physician's discretion)\n* Adequate blood results for treatment (at treating physician's discretion)\n* Starting a first line treatment\n\nExclusion Criteria:\n\n* History of prior or concurrent central nervous system metastases\n* History of other malignancy, except:\n\nMalignancy treated with curative intent and with no known active disease present for ≥ 3 years prior to randomization and felt to be at low risk for recurrence by the treating physician.\n\nAdequately treated non-melanomatous skin cancer or lentigo maligna without evidence of disease.\n\nAdequately treated cervical carcinoma in situ without evidence of disease. Prostatic intraepithelial neoplasia without evidence of prostate cancer\n\n* Prior chemotherapy or other systemic anticancer therapy for the treatment of metastatic colorectal carcinoma including but not limited to bevacizumab and anti-EGFR therapy (e.g. cetuximab, panitumumab, erlotinib, gefitinib, lapatinib)\n* Prior adjuvant chemotherapy (including oxaliplatin therapy) or other adjuvant systemic anticancer therapy including but not limited to bevacizumab and anti-EGFR therapy (e.g. cetuximab, panitumumab, erlotinib, gefitinib, lapatinib) for the treatment of colorectal cancer ≤ 6 months prior to randomization with the following exceptions: Subjects may have received prior fluoropyrimidine therapy if administered solely for the purpose of radiosensitization for the adjuvant or neoadjuvant treatment of rectal cancer.\n* Radiotherapy ≤ 14 days prior to randomization. Subjects must have recovered from all radiotherapy-related toxicities.","ALL","18 Years",{"count":142,"type":143},150,"ESTIMATED","INTERVENTIONAL",[146],"PHASE3","The FOLICOLOR trial aims to evaluate whether a liquid biopsy-guided follow-up strategy can improve outcomes in patients with unresectable, metastatic colorectal cancer (mCRC) receiving first-line systemic treatment. The approach uses NPY methylation-based circulating tumor DNA (ctDNA) analysis from blood samples to monitor treatment response and guide clinical decision-making. Eligible patients are adults diagnosed with unresectable, metastatic colorectal cancer who are starting first-line treatment. The primary goal is to demonstrate a clinically meaningful benefit, particularly in terms of quality of life (QoL) and reduction of treatment-related toxicity, by allowing earlier and more personalized therapeutic adjustments based on liquid biopsy findings.",[149],"Advanced Colorectal Cancer",[151,152,153],"NPY Methylation","Liquid Biopsy","advanced colorectal cancer patients","2026-04-22",{"date":156,"type":157},"2026-04-30","ACTUAL",{"date":159,"type":157},"2021-08-16",{"date":161,"type":143},"2031-08",{"name":5,"class":6},9]